Investigational drug · Phase 3
Olaparib phase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Recurrent Endometrial Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
363
Any phase or sponsor naming "Olaparib phase"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olaparib phase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Recurrent Endometrial Cancer
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Olaparib phase" as an intervention, largest first.
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06112379 · 1,902 participants · Start Nov 14, 2023 · Primary completion Nov 20, 2028
Drug: Dato-DXd; Durvalumab and 8 more · For: Breast Cancer
Sites: Daphne, Alabama; Prescott, Arizona; Jonesboro, Arkansas · 283 sites in all
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02032823 · 1,837 participants · Start Apr 22, 2014 · Primary completion Mar 27, 2020
Drug: Olaparib; Placebo · For: Breast Cancer
Sites: Anchorage, Alabama; Anchorage, Alaska; Gilbert, Arizona · 698 sites in all
- Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03737643 · 1,407 participants · Start Jan 4, 2019 · Primary completion Mar 17, 2025
Drug: Bevacizumab; Durvalumab and 4 more · For: Advanced Ovarian Cancer
Sites: Foothill Ranch, California; Los Angeles, California; Orange, California · 214 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03740165 · 1,367 participants · Start Dec 18, 2018 · Primary completion Aug 26, 2024
Drug: Pembrolizumab; Placebo for pembrolizumab and 6 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Sites: Birmingham, Alabama; Tucson, Arizona; Burbank, California · 227 sites in all
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02861573 · 1,200 participants (planned) · Start Nov 17, 2016 · Primary completion Oct 22, 2027
Drug: Pembrolizumab 200 mg; Olaparib 400 mg and 10 more · For: Metastatic Castration-Resistant Prostate Cancer
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT03182634 · 1,150 participants (planned) · Start Dec 15, 2016 · Primary completion Nov 2022
Drug: Fulvestrant; Neratinib and 3 more · For: Advanced Breast Cancer
Sites: Sutton, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.